Report of
FNCA FY2024 Workshop on Radiation Oncology

Outline of Workshop

The FNCA FY2024Workshop on Radiation Oncology was held from 26th-28th October 2024, in Bangkok, Thailand. The meeting was co-organized by the Siriraj Hospital, Mahidol University, Thailand Institute of Nuclear Technology (TINT) and the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). Representatives from 11 FNCA member countries, namely Bangladesh, China, Indonesia, Japan, Kazakhstan, Korea, Malaysia, Mongolia, Philippines, Thailand and Vietnam participated in the workshop.
This project carries out several international joint clinical studies in order to establish treatment protocols for uterine cervix cancer, nasopharyngeal cancer and breast cancer, which affect large number of people in FNCA member countries, and finally to improve the technique of radiation oncology in the Asian region. The project recently launched 2 new clinical studies on palliative radiotherapy.

Opening Session

Dr. JITWATCHARAKOMOL Tanun, Medical Doctor, Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Faculty of Medicine, Mahidol University moderated the session.

Asst. Prof. VONGVIRIYANGKOON Tara, Deputy Dean, Faculty of Medicine, Siriraj Hospital, Mahidol University gave participants a welcome address.
Mr. WADA Tomoaki, FNCA Advisor of Japan delivered an opening address.
Mr. KAWAHARA Taku, Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) delivered an opening remark.
Prof. KATO Shingo, the Project Leader of Radiation Oncology Project gave his remark.
Assoc. Prof. CHANSILPA Yaowalak, Project Leader of Thailand, Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Faculty of Medicine, Mahidol University gave her welcome address.

Prof. Chanitra Thuwajit, Department of Immunology, Faculty of Medicine, Siriraj Hospital, Mahidol University delivered a special lecture on Cancer Immunotherapy.

Prospective Observational Study of 3D-Image Guided Brachytherapy for Locally Advanced Cervical Cancer (CERVIX-V)

This is a protocol for cervical cancers following Cervix-IV. The patient enrollment started in 2017.

Dr. OKONOGI Noriyuki, Juntendo University Graduate School of Medicine presented the protocol of CERVIX-V and the clinical outcomes.

From May 2017 to October 2023, 108 patients were enrolled in CERVIX-V. Out of these, 99 patients were eligible. Case enrollment from member countries are followings: Bangladesh (2), China (16), Indonesia (9), Japan (13), Kazakhstan (8), Korea (0), Mongolia (4), Malaysia (11), the Philippines (8), Thailand (32) and Vietnam (5).

As per the preliminary analysis of Cervix-V, 99 patients with median follow-up of 37.0 months were analyzed. All patients were treated with 3D-IGBT. Among them, 34 patients were treated with the interstitial technique. Compared to the reference doses, 90% of cases that satisfied the dose constraints in all items.

Regarding toxicities, grade 3 acute hematological toxicity was observed in 27 (27%) patients, and grade 3 acute non-hematological toxicity was observed in 3 (3%) patients. No grade 4 or severe acute toxicity was observed. No patients developed grade 3 or worse treatment-related late toxicity.

With a median follow-up time of 37.0 months, the 2-year, locoregional control (LC), progression-free survival (PFS), and overall survival (OS) were 93.6%, 76.7%, and 89.6%, respectively. Local recurrence occurred in 11 cases by the last observation date.

- Prof. OHNO Tatsuya, Gunma University Graduate School of Medicine announced that the target number of patients for CERVIX-V have been achieved, a follow-up of at least one year was encouraged as per the protocol. The proposal to publish papers on the results of CERVIX-V at the appropriate time was also approved.

- Discussion on the overall treatment time, details of local recurrence, the definition of DFS, analysis of the cause of death, and the need for long-term analysis was raised.

QA/QC for 3D-IGBT

This activity aims to put in place reliable dosimetry in the institutes among the member countries for effective joint clinical studies. The audits in Quality Assurance (QA)/Quality Control (QC) of dosimetry measurement and radiation calibration have been conducted, which is for the reliable radiotherapy.

Dr. MIZUNO Hideyuki, QST and Dr. NAKAJI Taku, QST gave the preliminary report of the on-site 3D-IGBT audit at Siriraj Hospital. The auditing results of the end-to-end test, applicator offset value, and source strength were demonstrated within the acceptable criteria.

Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Postmastectomy Radiation Therapy (PMRT) & (Whole Breast Irradiation (WBI) /BREAST-I)

Prof. KARASAWA Kumiko, Tohto University presented the summary of analyzed clinical data of PMRT / BREAST-I which has been published on the journal of Clinical Oncology.

PMRT /BREAST-I

From February 2013 to October 2019, 222 cases were registered. The number of patients registered from Bangladesh (84), China (13), Indonesia (0), Japan (15), Kazakhstan (20), Korea (0), Malaysia (0), Mongolia (26), Philippines (18), Thailand (0) and Vietnam (46). The follow up period is 1 to 114 months with a median of 64 months. The late adverse effects of skin G1 (42%), G2 (1%); subcutaneous tissue G1 (16%), G2 (2%); breast G1 (5%); lung G1 (6%); heart G1 (2%). There were 7 loco-regional recurrences, 33 distant metastases, 23 breast cancer deaths and 11 intercurrent deaths. The five-year loco-regional control, progression free survival and overall survival rates are 97%, 84.6% and 90.5%, respectively. Upper limb edema was measured and evaluated in 77 cases (35%), with 89.6% of cases either having a difference of 2 cm or more between the left and right sides or having subjective symptoms of edema.

WBI /BREAST-I

From February 2013 to October 2018, 227 cases were registered. The registered numbers were Bangladesh (31), China (6), Indonesia (16), Japan (134), Kazakhstan (14), Korea (9), Malaysia (0), Mongolia (3), Philippines (0), Thailand (14) and Vietnam (0). All patients with 228 tumors completed the protocol treatment and was analyzed. The acute adverse effects of skin G1 (80%), G2 (11%), G3 (2%); subcutaneous tissue G1 (11%); lung G1 (1%). The follow up period is 6 to 113 months with a median of 76 months. The late adverse effects of skin G1 (21%), G2 (1%); subcutaneous tissue G1 (10%); breast G1 (9%); lung G1 (2%). The cosmetic outcome were excellent (148), good (74), fair (3) and poor (3) in patients with more than 3 years follow-up.

Two loco-regional recurrence, 7 distant metastases, 3 breast cancer death and 9 intercurrent death have been observed. The 5-year LC, PFS survival and OS are 99.6%, 95.1% and 96.1%, respectively.

An open discussion on the clinical data of BREAST-I followed. Both PMRT and WBI follow-up period will be extended from 5 to 10 years.

Palliative Radiotherapy for Bone Metastasis (BONE-I)

Dr. MAKISHIMA Hirokazu, QST reviewed the newly started research study on Palliative radiotherapy for Bone Metastasis (BONE-I).

• 6 facilities participated with 142 cases registered within 3 months
• More than 50 % of the responses preferred 30 Gy in 10 fractions, followed by 20 Gy in 5 fractions and only 4% preferred 8 Gy single fraction.
• While 2023 survey showed deteriorated PS, short life expectancy and long distance patient travel were reasons favoring single fraction RT, 8 Gy single fraction was not preferred in cases with either of these factors showing discrepancy in our decision making.
• While reasons of these discrepancies remain unclear, we agreed on performing a follow-up questionnaire 2 years later (3 years from last survey) to see the change in the trend.

Prof. WAKATSUKI Masaru, QST presented an IAEA/RCA project survey on Palliative Radiation Treatment.

Palliative Radiotherapy for Brain Metastasis (BRAIN-I)

Dr. Kullathorn Thephamongkhol, Associate Professor, Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Mahidol University presented the protocol of BRAIN-I (Added Survival Benefit of Palliative Whole Brain Radiotherapy in Non-Small Cell Lung Cancer: An External Validation and model updating of a Prediction Model).

Dr. Kullathorn Thephamongkhol and Siriraj’s team presented the background and methodology; how to send and check the data; the reasons behind case record form and research highlight and call to action. The study design and schema for the prognostic multivariable modeling study were presented.

The number of target cases enrolled is 800 cases. Current status until 16th November 2024, 496 patients were enrolled in BRAIN-I. Out of these, 233 patients were eligible, and 26 patients were under review. Case enrollment from member countries are as follows: China (20), Indonesia (1), Japan (7), the Philippines (5), and Thailand (200).

New Clinical Study and New Research Study

A clinical study of concurrent chemoradiotherapy using whole pelvic IMRT and 3D-IGBT for locally advanced cervical cancer (CERVIX-VI) was proposed by Prof. OHNO Tatsuya. The concept of this new clinical trial and the results of the preliminary questionnaire were presented.

All members approved that CERVIX-VI is conducted as an observational study. The basic policy (dose constraints) for radiation therapy reached a consensus. The patients’ selection, the scope of prophylactic irradiation, and whether to allow overlapping registration with other clinical trials were discussed. The protocol was scheduled to be finalized at next year's workshop.

An idea to conduct a questionnaire-based survey for preoperative short course radiotherapy for locally advanced rectal cancer was proposed by Dr. Rosdiana binti Abd Rahim, Clinical Oncologist, National Cancer Institute, Malaysia. Various factors were discussed in relation to preoperative treatment for rectal cancer. Specifically, target patients, difference in the time to surgery, chemotherapy regimens, and the timing of radiotherapy were discussed. The preparation of the questionnaire-based survey will be prepared by Dr. Rosdiana.

Another idea to conduct a questionnaire-based survey for post-operative ultra-hypofractionated radiotherapy for breast cancer was proposed by Prof. KARASAWA Kumiko. The specific target patients and boost irradiation doses, and QA/QC were discussed. The preparation of the questionnaire-based survey will be prepared by Prof. Karasawa.

Future Plans

Prof. KATO Shingo presented the future plans and next activities.
**See the WS Minutes for the details.

It was agreed that the next workshop is to be held in October 2025.

Drafting Workshop Minutes

The draft of the minutes was submitted by rapporteurs, discussed and amended. The draft of the minutes will be circulated after the workshop and will be finalized.

Technical Visit to Siriraj Radiation Oncology

Technical visit was held at the Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University.

Open Lectures

Open Lectures was held at Siriraj Hospital, as a part of the workshop on the last day. There were 5 lectures on the theme of 1) Recent Developments in FNCA 2) Radiation Oncology and international collaboration among Asian countries 3) 3D-IGBT for cervical cancer; CT-based contouring guideline 4) Radiotherapy for Hepatocellular Carcinoma 5) Respiratory motion management in treatment planning using 4D CT imaging targeting lung and/or liver cancer 6) Particle beam therapy in cancer radiotherapy 7) Clinical Reasoning: For Trainers and Trainees.

Minutes of
FNCA FY2024 Workshop on Radiation Oncology Project

(1) Following the agreement at the 24th Forum for Nuclear Cooperation in Asia (FNCA) Coordinators Meeting, the FNCA FY2024 Workshop on Radiation Oncology was held from 26th to 28th November 2024, in Bangkok, Thailand. The meeting was co-organized by the Siriraj Hospital, Mahidol University, Thailand Institute of Nuclear Technology (TINT) and the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). Representatives from 11 FNCA member countries, namely Bangladesh, China, Indonesia, Japan, Kazakhstan, Korea, Malaysia, Mongolia, Philippines, Thailand and Vietnam participated in the workshop.

Opening Ceremony

(2) Dr. JITWATCHARAKOMOL Tanun, Medical Doctor, Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Faculty of Medicine, Mahidol University moderated the session.

Asst. Prof. VONGVIRIYANGKOON Tara, Deputy Dean, Faculty of Medicine, Siriraj Hospital, Mahidol University gave participants a welcome address.

Mr. WADA Tomoaki, FNCA Advisor of Japan delivered an opening address.

Mr. KAWAHARA Taku, Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) delivered an opening remark.

Prof. KATO Shingo, the Project Leader of Radiation Oncology Project gave his remark.

Assoc. Prof. CHANSILPA Yaowalak, Project Leader of Thailand, Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Faculty of Medicine, Mahidol University gave her welcome address.

(3) Introduction of individual participants followed.

(4) The agenda was adopted and chairpersons and rapporteurs were selected.

(5) Prof. THUWAJIT Chanitra, Department of Immunology, Faculty of Medicine, Siriraj Hospital, Mahidol University delivered a special lecture on Cancer Immunotherapy.

(6) Prof. PITHUKPAKORN Manop, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University gave a special lecture on Cancer Precision Medicine.

Session 1: Prospective Observational Study of 3D-Image Guided Brachytherapy for Locally Advanced Cervical Cancer (CERVIX-V)

(7) Dr. OKONOGI Noriyuki, Associate Professor, Department of Radiation Oncology, Juntendo University Graduate School of Medicine presented the protocol of CERVIX-V and the clinical outcomes.

The number of target cases enrolled is 100 cases. From May 2017 to October 2023, 108 patients were enrolled in CERVIX-V. Out of these, 99 patients were eligible. Case enrollment from member countries are followings: Bangladesh (2), China (16), Indonesia (9), Japan (13), Kazakhstan (8), Korea (0), Mongolia (4), Malaysia (11), the Philippines (8), Thailand (32) and Vietnam (5).

As per the preliminary analysis of Cervix-V, 99 patients with median follow-up of 37.0 months were analyzed. All patients were treated with 3D-IGBT. Among them, 34 patients were treated with the interstitial technique. Compared to the reference doses, 90% of cases that satisfied the dose constraints in all items.

Regarding toxicities, grade 3 acute hematological toxicity was observed in 27 (27%) patients, and grade 3 acute non-hematological toxicity was observed in 3 (3%) patients. No grade 4 or severe acute toxicity was observed. No patients developed grade 3 or worse treatment-related late toxicity.

With a median follow-up time of 37.0 months, the 2-year, locoregional control (LC), progression-free survival (PFS), and overall survival (OS) were 93.6%, 76.7%, and 89.6%, respectively. Local recurrence occurred in 11 cases by the last observation date.

(8) An open discussion on CERVIX-V followed.
- Prof. OHNO Tatsuya, Professor and Chairperson Department of Radiation Oncology, Gunma University Graduate School of Medicine announced that the target number of patients for CERVIX-V have been achieved, a follow-up of at least one year was encouraged as per the protocol. The proposal to publish papers on the results of CERVIX-V at the appropriate time was also approved.

- Discussion on the overall treatment time, details of local recurrence, the definition of DFS, analysis of the cause of death, and the need for long-term analysis was raised.

Session 2: QA/QC for 3D-IGBT

(9) Dr. MIZUNO Hideyuki, Section Manager, Radiation Quality Control Section, QST Hospital, QST and Dr. NAKAJI Taku, Researcher, Radiation Quality Control Section, QST Hospital, QST gave the preliminary report of the on-site 3D-IGBT audit at Siriraj Hospital. The auditing results of the end-to-end test, applicator offset value, and source strength were demonstrated within the acceptable criteria.

(10) An open discussion followed.

Phase II Study of Neoadjuvant Chemotherapy with Concurrent Chemoradiotherapy (CCRT) for Nasopharyngeal Carcinoma (NPC-III)

(11) Dr. MAKISHIMA, Hirokazu, Chief physician, QST Hospital, National Institutes for Quantum Science and Technology, reviewed the draft of the final report to be submitted to an international journal. All attendees agreed on the publication and the authorship. The agreed order of priority as follows: Tier 1; one from each facility, project leader (Prof. Kato), lead investigator (Prof. Ohno), Dr. Makishima, Tier 2; second author from each facility, Tier 3; Other delegates. Priority within each tier would be determined by contributed cases to the study.

(12) Discussion was followed by outcome comparison with NPC-I study. Preliminary propensity matched analysis showed a benefit in overall survival though no significant difference in local recurrence nor distant metastasis rate. There were comments to this issue and an in-depth review of the recurred cases was suggested.

Lunch Session

(13) Dr SEKINO Yuta, National Cancer Center Hospital, Japan gave a lecture on the ATLAS Project.

Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Postmastectomy Radiation Therapy (PMRT) & (Whole Breast Irradiation (WBI) /BREAST-I)

(14) Prof. KARASAWA Kumiko, Tohto University presented the summary of analyzed clinical data of PMRT / BREAST-I which has been published on the journal of Clinical Oncology. The summary is as follows:

From February 2013 to October 2019, 222 cases were registered. The number of patients registered from Bangladesh (84), China (13), Indonesia (0), Japan (15), Kazakhstan (20), Korea (0), Malaysia (0), Mongolia (26), Philippines (18), Thailand (0) and Vietnam (46). The follow up period is 1 to 114 months with a median of 64 months. The late adverse effects of skin G1 (42%), G2 (1%); subcutaneous tissue G1 (16%), G2 (2%); breast G1 (5%); lung G1 (6%); heart G1 (2%). There were 7 loco-regional recurrences, 33 distant metastases, 23 breast cancer deaths and 11 intercurrent deaths. The five-year loco-regional control, progression free survival and overall survival rates are 97%, 84.6% and 90.5%, respectively. Upper limb edema was measured and evaluated in 77 cases (35%), with 89.6% of cases either having a difference of 2 cm or more between the left and right sides or having subjective symptoms of edema.

(15) Next, Prof. KARASAWA presented the summary of the analyzed clinical data of WBI / BREAST-I followed. The summary is as follows.

From February 2013 to October 2018, 227 cases were registered. The registered numbers were Bangladesh (31), China (6), Indonesia (16), Japan (134), Kazakhstan (14), Korea (9), Malaysia (0), Mongolia (3), Philippines (0), Thailand (14) and Vietnam (0). All patients with 228 tumors completed the protocol treatment and was analyzed. The acute adverse effects of skin G1 (80%), G2 (11%), G3 (2%); subcutaneous tissue G1 (11%); lung G1 (1%). The follow up period is 6 to 113 months with a median of 76 months. The late adverse effects of skin G1 (21%), G2 (1%); subcutaneous tissue G1 (10%); breast G1 (9%); lung G1 (2%). The cosmetic outcome were excellent (148), good (74) , fair (3) and poor (3) in patients with more than 3 years follow-up.
Two loco-regional recurrence, 7 distant metastases, 3 breast cancer death and 9 intercurrent death have been observed. The 5-year LC, PFS survival and OS are 99.6%, 95.1% and 96.1%, respectively.

An open discussion on the clinical data of BREAST-I followed. Both PMRT and WBI follow-up period will be extended from 5 to 10 years.

Session 4: Palliative Radiotherapy for Bone Metastasis (BONE-I)

(16) Dr. MAKISHIMA Hirokazu reviewed the newly started research study on Palliative radiotherapy for Bone Metastasis (BONE-I).
He also presented the results of the first survey conducted prior to the workshop. The summary of the results is as follows.

• 6 facilities participated with 142 cases registered within 3 months
• More than 50% of the responses preferred 30 Gy in 10 fractions, followed by 20 Gy in 5 fractions and only 4% preferred 8 Gy single fraction.
• While 2023 survey showed deteriorated PS, short life expectancy and long distance patient travel were reasons favoring single fraction RT, 8 Gy single fraction was not preferred in cases with either of these factors showing discrepancy in our decision making.
• While reasons of these discrepancies remain unclear, we agreed on performing a follow-up questionnaire 2 years later (3 years from last survey) to see the change in the trend.

(17) Discussion followed.

(18) Prof. WAKATSUKI Masaru, Deputy Director General, QST Hospital, National Institutes for Quantum Science and Technology (QST) presented an IAEA/RCA project survey on Palliative Radiation Treatment.

(19) An open forum followed.

Session 5: Palliative Radiotherapy for Brain Metastasis (BRAIN-I)

(20) Dr THEPHAMONGKHOL Kullathorn, Associate Professor, Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Mahidol University presented the protocol of BRAIN-I (Added Survival Benefit of Palliative Whole Brain Radiotherapy in Non-Small Cell Lung Cancer: An External Validation and model updating of a Prediction Model).

(21) Dr THEPHAMONGKHOL Kullathorn and Siriraj’s team presented the background and methodology; how to send and check the data; the reasons behind case record form and research highlight and call to action. The study design and schema for the prognostic multivariable modeling study were presented.

(22) The number of target cases enrolled is 800 cases. Current status until 16th November 2024, 496 patients were enrolled in BRAIN-I. Out of these, 233 patients were eligible, and 26 patients were under review. Case enrollment from member countries are as follows: China (20), Indonesia (1), Japan (7), the Philippines (5), and Thailand (200).

(23) Dr THEPHAMONGKHOL Kullathorn presented the proposed action plan for the study. IRB submission would be until March 2025. Full data collection until October 2025. Data collection cohort of consecutive patients of brain metastasis in NSCLC with and without whole brain RT retrospectively from Jan 2020 to now. October 2025-October 2026 would be analysis of data. Publication will be in 2026 because no long follow-up is needed. Every country was asked to contribute data to this study at least 25-30 patients/country.

(24) An open discussion on the clinical data of BRAIN-I followed.
- Prof. KATO, Shingo would like to clarify about the drug with intracranial activity.
- Prof. OHNO, Tatsuya asked the target of patient enrollment and emphasized the patient could be included at different timeline.

Session 6: New Clinical Study and New Research Study

(25) A clinical study of concurrent chemoradiotherapy using whole pelvic IMRT and 3D-IGBT for locally advanced cervical cancer (CERVIX-VI) was proposed by Prof. OHNO Tatsuya. The concept of this new clinical trial and the results of the preliminary questionnaire were presented.

All members approved that CERVIX-VI is conducted as an observational study. The basic policy (dose constraints) for radiation therapy reached a consensus. The patients’ selection, the scope of prophylactic irradiation, and whether to allow overlapping registration with other clinical trials were discussed. The protocol was scheduled to be finalized at next year's workshop.

An idea to conduct a questionnaire-based survey for preoperative short course radiotherapy for locally advanced rectal cancer was proposed by Dr. ROSDIANA binti Abd Rahim, Clinical Oncologist, National Cancer Institute, Malaysia. Various factors were discussed in relation to preoperative treatment for rectal cancer. Specifically, target patients, difference in the time to surgery, chemotherapy regimens, and the timing of radiotherapy were discussed. The preparation of the questionnaire-based survey will be prepared by Dr. Rosdiana.

Another idea to conduct a questionnaire-based survey for post-operative ultra-hypofractionated radiotherapy for breast cancer was proposed by Prof. KARASAWA Kumiko. The specific target patients and boost irradiation doses, and QA/QC were discussed. The preparation of the questionnaire-based survey will be prepared by Prof. KARASAWA.

Session 7: Future Plans

(26) Prof. KATO Shingo presented the future plans and next activities.

1. Next workshop will be held in Astana, Kazakhstan on October 13-17, 2025.
2. Clinical Studies
   • Cervix-V: Evaluate 2-year outcome (primary endpoint). Publish the 1st report. Continue follow-up and evaluate long term outcome.
   • Breast-I: Revise the protocol (endpoint: 5-year to 10-year outcome). Continue follow-up to evaluate 10-year outcome
   • Bone-I: follow up survey 2 years later
   • Brain-I: continue to input more data and evaluate the outcome at the next workshop
   • Cervix-VI: Finalize the study protocol at the next workshop
   • Breast-II Ultra-Hypofractionated radiotherapy for post-operative breast cancer: A preliminary survey questionnaire was proposed for distribution to participating countries.
3. Hands-on training on 3D-IGBT
   • Hold training session at the next workshop
4. QA/QC of 3D-IGBT
   • Continue on-site audits of 3D-IGBT
   • Report the results at the next workshop
5. Other activities
   • Collaboration with IAEA/RCA: Continue collaboration RCA/RAS 6098

Session 8: Drafting Workshop Minutes

(27) The WS participants reviewed workshop discussion.

The draft of the minutes was submitted by rapporteurs, discussed and amended. The draft of the minutes will be circulated after the workshop and will be finalized.

(28) Prof. KATO Shingo gave the closing remarks and thanked all the participants.

Session 9: Technical Visit to Siriraj Radiation Oncology

(29) Technical visit was held at the Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University.

Session 10: Open Lectures

(30) On the last day of the workshop, Open Lectures was held at Siriraj Hospital.

(31) Dr THEPHAMONGKHOL Kullathorn moderated the session with Dr. SETAKORNNUKUL Jiraporn, Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University.

(32) Mr. WADA Tomoaki gave a presentation about the Recent Developments in FNCA.

(33) Prof. KATO Shingo delivered a lecture on Radiation Oncology and international collaboration among Asian countries; FNCA Radiation Oncology Project.

(34) Prof. OHNO, Tatsuya gave a lecture on 3D-IGBT for cervical cancer; CT-based contouring guideline.

(35) Dr. MAKISHIMA Hirokazu delivered a lecture entitled Radiotherapy for Hepatocellular Carcinoma.

(36) Prof. KIM Kum Bae, Chief Medical Physicist & Principal Researcher Radiation Oncology Department, Korea Institute of Radiological & Medical Sciences (KIRAMS) gave a lecture on Respiratory Motion Management in
Treatment Planning using 4D CT Imaging Targeting Lung and/or Liver Cancer.

(37) Prof. WAKATSUKI, Masaru delivered a lecture on Particle Beam Therapy in Cancer Radiotherapy.

(38) Dr. NG, Winnie Nyek Ping, Clinical Oncologist, National Cancer Institute shared her experiences on Clinical Reasoning: For Trainers and Trainees.

(39) Assoc. Prof. CHANSILPA Yaowalak concluded the Open Lecture with her closing remarks.

Program of
FNCA FY2024 Workshop on Radiation Oncology

Day 1 Tue, 26th November 2024
Place: Siriraj Hospital Siriraj Hospital, Faculty of Medicine,
Mahidol University

Day 2 Wed, 27th November 2024
Place: Siriraj Hospital, Faculty of Medicine,
Mahidol University

Day 3 Thu, 28th November 2024
Place: Siriraj Hospital, Faculty of Medicine,
Mahidol University

Leave from Hotel & Move to Siriraj Hospital